Cryoport, Inc.

Cryoport, Inc. ( CYRX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Mark W. Sawicki - Senior VP & Chief Scientific Officer Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Philip Seunghwa Song - Leerink Partners LLC, Research Division Steven Etoch - Stephens Inc., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division David Larsen - BTIG, LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, and welcome to Cryoport's Third Quarter 2026 Earnings Call.

CryoPort NASDAQ: CYRX raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products.

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.

Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026 Raises full-year 2026 revenue guidance to $197 million - $199 million NASHVILLE, Tenn., Nov. 5, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.